Wolfe Research analyst Justin Lake upgraded Elevance Health (ELV) to Outperform from Peer Perform with a $425 price target The firm is “increasingly confident” in the company’s near-term upside opportunities, first in Medicare Advantage in 2026, then with the healthcare exchanges in 2027. Wolfe believes improving investor sentiment will drive upside in the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Trump Trade: Trump says Venezuela to give U.S. up to 50M barrels of oil
- Elevance Health price target raised to $424 from $403 at Wells Fargo
- Trump says he will meet with 14 health insurers in a few days
- Elevance Health price target raised to $431 from $412 at Bernstein
- Elevance Health price target raised to $404 from $385 at Barclays